On December 5th, Southern Finance and Economics reported that Iskra Reic, the newly appointed Global Executive Vice President and International Business Head of AstraZeneca, announced in an internal letter that Lin Xiao will be appointed as the General Manager of AstraZeneca China, and Guan Dongmei will be appointed as the General Manager of AstraZeneca China's Oncology Business. Lin Xiao and Guan Dongmei will become members of the global management teams for the Biopharmaceutical Business Unit and the Oncology Business Unit, respectively. Lin Xiao, Guan Dongmei, and Hu Yiqing, Vice President of AstraZeneca China and Head of Rare Diseases Division, will all report directly to Iskra Reic, Executive Vice President and Head of International Business at AstraZeneca. In addition, according to AstraZeneca's disclosure to reporters, Lai Minglong serves as the head of AstraZeneca's global oncology business Dato DXd and lung cancer business unit, reporting to Mr. Sunil Verma, AstraZeneca's senior vice president and head of the oncology business unit. (21st Century Business Herald)